ARX788 in HER2-positive Metastatic Breast Cancer Patients
NCT06663748 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44
Last updated 2024-10-29
Summary
A phase 2 study of ARX788 given every 6 weeks in HER2-positive, metastatic breast cancer patients.
Conditions
- HER2-positive, Metastatic Breast Cancer
Interventions
- DRUG
-
ARX788
2.2 mg/kg IV infusion on Day 1 of each 42-day treatment cycle.
Sponsors & Collaborators
-
Henan Cancer Hospital
lead OTHER_GOV
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-11-20
- Primary Completion
- 2025-11-20
- Completion
- 2029-11-20
- FDA Drug
- Yes
More Related Trials
-
Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer
NCT03084237 ·Status: COMPLETED ·Phase: PHASE3
-
Study of TFX06 in Women With Advanced Breast Cancer.
NCT05927779 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer
NCT02030678 ·Status: UNKNOWN ·Phase: PHASE2
-
RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer
NCT05134519 ·Status: UNKNOWN ·Phase: PHASE2
-
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
NCT05429684 ·Status: UNKNOWN ·Phase: PHASE3
-
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
NCT06057610 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Real-World Study of Pyrrolitinib Maleate Tablets for HER-2-Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab Therapy
NCT06470347 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of ARRY-380 in Patients With Advanced HER2+ Cancer
NCT00650572 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of RC48-ADC in Subjects With Advanced Breast Cancer
NCT03052634 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients
NCT05263869 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
NCT06210776 ·Status: RECRUITING
-
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
NCT05514717 ·Status: RECRUITING ·Phase: PHASE1
-
Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer
NCT04917900 ·Status: UNKNOWN ·Phase: PHASE2
-
A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance
NCT07321015 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases
NCT03500380 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Reverse HER2-negative Immune Resistant Breast Cancer
NCT06731140 ·Status: RECRUITING ·Phase: PHASE2
-
Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC
NCT07007780 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer
NCT07121244 ·Status: RECRUITING ·Phase: PHASE1
-
B002 in Patients With HER2-positive Breast Cancer
NCT04382352 ·Status: COMPLETED ·Phase: PHASE1
-
Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer
NCT06693024 ·Status: RECRUITING
-
A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
NCT04296370 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
NCT06609187 ·Status: RECRUITING ·Phase: PHASE1
-
Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer
NCT06711055 ·Status: RECRUITING
-
Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes
NCT07187752 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients
NCT06700369 ·Status: RECRUITING